Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates

INIS

• weight 100%
• lipids 100%
• pregnancy 100%
• ovaries 100%
• ovulation 100%
• control 60%
• comparative evaluations 60%
• insulin 60%
• levels 40%
• women 40%
• interventions 40%
• side effects 40%
• sensitivity 40%
• fasting 40%
• exercise 40%
• androgens 40%
• assessments 20%
• patients 20%
• drugs 20%
• blood 20%
• testosterone 20%
• hormones 20%
• design 20%
• losses 20%
• sugar 20%
• sulfates 20%
• globulins 20%
• dehydroepiandrosterone 20%

Medicine and Dentistry

• Lipid 100%
• Pregnancy Rate 100%
• Polycystic Ovarian Syndrome 100%
• Orlistat 100%
• Glycon 72%
• Ovulation 45%
• Insulin Resistance 18%
• Body Weight Loss 18%
• Anthropometry 18%
• Lifestyle Intervention 18%
• Conception 18%
• Androgen 18%
• Side Effect 18%
• Homeostatic Model Assessment 9%
• Body Mass Index 9%
• Arm 9%
• Waist-Hip Ratio 9%
• Randomized Controlled Trial 9%
• Prasterone Sulfate 9%
• Hormone Binding Protein 9%
• Insulin 9%
• Testosterone 9%
• Treatment Group 9%

Nursing and Health Professions

• Tetrahydrolipstatin 100%
• Lipid 100%
• Syndrome 100%
• Pregnancy Rate 100%
• Metformin 72%
• Anthropometric Parameters 18%
• Body Weight Loss 18%
• Insulin Resistance 18%
• Side Effect 18%
• Androgen 18%
• Body Mass 9%
• Waist Hip Ratio 9%
• Homeostasis Model Assessment 9%
• Hormone Blood Level 9%
• Waist Circumference 9%
• Treatment Group 9%
• Efficacy 9%
• Insulin 9%
• Testosterone 9%
• Hormone Binding Protein 9%
• Prasterone Sulfate 9%